Walk into a long-term psychiatric ward in almost any country and one statistic stands out: most patients smoke. Population studies put the rate of current smoking among people with schizophrenia somewhere between 50 and 70 percent, depending on country and sampling method, compared with around 11 percent of US adults overall in recent CDC data. The gap has narrowed slightly as smoking has fallen in the general population, but it has not closed. Tobacco-related disease is now the leading preventable cause of early death in this population — outweighing suicide, accidents, and overdose combined.
People with schizophrenia smoke at roughly 2 to 3 times the general population rate due to a combination of neurobiology, social factors, and historical psychiatric culture — and effective cessation treatment exists.
What the data actually says
A widely cited meta-analysis by de Leon and Diaz (Schizophrenia Research, 2005) pooled 42 studies across 20 countries and found a smoking prevalence of 62 percent among people with schizophrenia, with an odds ratio of 5.3 compared with general population controls. More recent reviews summarised by the SAMHSA National Survey on Drug Use and Health show that adults with any serious mental illness consume roughly 31 percent of all cigarettes sold in the US, despite making up around 5 percent of adults. Daily cigarette counts are also higher: people with schizophrenia who smoke tend to extract more nicotine per cigarette through deeper inhalation and shorter inter-puff intervals.
The biology: nicotine and the schizophrenia brain
Decades of research suggest that nicotine briefly improves several cognitive deficits associated with schizophrenia. The strongest evidence is for P50 sensory gating — a measure of the brain's ability to filter out repeated, irrelevant stimuli. People with schizophrenia consistently show impaired P50 gating, and nicotine partially normalises it through stimulation of α7 nicotinic acetylcholine receptors. Adler and colleagues at the University of Colorado have published extensively on this, including in the American Journal of Psychiatry.
Nicotine also briefly improves working memory, sustained attention, and reaction time in many people with schizophrenia. It speeds the metabolism of several antipsychotics through induction of the CYP1A2 liver enzyme, which means people who smoke often need higher doses of olanzapine, clozapine, or haloperidol than non-smokers to reach the same blood level. The caffeine and clozapine article covers a related interaction.
This package of effects has historically been called the self-medication hypothesis — the idea that people with schizophrenia smoke partly to compensate for cognitive symptoms or to dampen medication side effects, especially extrapyramidal symptoms. The hypothesis is not the whole story, but it captures something real that pure willpower-based smoking-cessation framings miss.
The social and historical layer
For most of the 20th century, cigarettes were currency on psychiatric wards. They were used to reward behaviour, to facilitate group bonding, and as one of the few pleasures available during long admissions. Smoking rooms were standard. Many adults with schizophrenia first started smoking heavily in inpatient settings. Even today, despite smoke-free hospital policies, the cultural association between psychiatric care and smoking persists in a way it does not for, say, oncology wards.
Layered on top: poverty, marginal housing, peer networks dominated by other smokers, limited access to cessation services, and a long-running clinical myth that "they have enough to cope with — don't take their cigarettes too." That last one has been thoroughly debunked. The NICE 2021 guideline on tobacco explicitly recommends that smoking cessation be offered to all people in mental health services using the same evidence-based methods as the general population, with extra support if needed.
What it costs
The mortality data is stark. People with schizophrenia die roughly 10 to 25 years earlier than general population peers, and cardiovascular and respiratory disease account for the majority of that gap. Smoking is the single largest modifiable contributor. A landmark Swedish national-registry study by Olfson and colleagues (JAMA Psychiatry, 2015) found that among people with schizophrenia, the standardised mortality ratio for cardiovascular disease was nearly 4, and most of that excess was attributable to smoking and metabolic factors.
Financially, in the US a pack-a-day smoker on disability income often spends 20 to 30 percent of their monthly cash on tobacco. That money is not theoretical — it is rent, food, transport to clinic appointments, and the small everyday choices that make a life feel possible.
Quitting is harder, but not categorically harder
People with schizophrenia who try to quit smoking have lower long-term abstinence rates than the general population, but the difference is smaller than many clinicians assume. Meta-analyses suggest that with appropriate support, around 20 to 30 percent of motivated quitters with schizophrenia maintain abstinence at six to twelve months — compared with around 30 to 40 percent in the general population. The gap closes substantially when treatment is intensive and tailored.
What actually works
The combination with the strongest evidence is:
- Varenicline (Chantix) — a partial α4β2 nicotinic receptor agonist, with the highest single-agent quit rates and good safety data in schizophrenia from the EAGLES trial (Anthenelli et al., The Lancet, 2016).
- Nicotine replacement therapy in adequate doses — usually patch plus a short-acting form (gum, lozenge, inhaler).
- Bupropion — somewhat less effective than varenicline but a reasonable alternative.
- Behavioural support — quit lines, group programs, or one-to-one counselling. People who get behavioural plus pharmacological support quit at roughly twice the rate of those who use either alone.
Frida's view — and the position taken by NICE, SAMHSA, and the US National Cancer Institute — is that being on antipsychotic medication is not a contraindication to any of these. See our deeper articles on nicotine replacement and cessation strategies for the practical detail.
Critical: the medication interaction
Tobacco smoke induces CYP1A2 and lowers blood levels of clozapine, olanzapine, and several other antipsychotics. Quitting suddenly can roughly double clozapine levels within a week, sometimes producing severe sedation or seizures. Tell your prescriber before you quit so they can plan a dose adjustment and consider a clozapine level check.
What to ask your prescriber
- Am I on a medication whose dose will need to change if I stop smoking?
- Would varenicline or NRT be a reasonable starting point for me?
- Can you refer me to a tobacco treatment specialist or quit line?
- What is your plan for monitoring my mood and symptoms during the first few weeks?
The bigger picture
Smoking in schizophrenia is not a moral failing or evidence of weak motivation. It is a real biological pull layered on top of decades of social and clinical history. Treating it well requires taking both the biology and the lived experience seriously — and offering the same evidence-based help that anyone else would get, plus a little extra when needed.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.